# A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC

Source: https://onco.cc/trials/nct06812260/  
OnCo record `nct06812260` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX10+chemo in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.

## Summary

A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT06812260 by Shanghai Henlius Biotech, with 26 participants enrolled, started 2025-06-24 and due to reach its primary completion in 2026-10-22. Interventions recorded: HLX10+chemo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06812260
- Phase: 2
- Setting: A Single-arm, Open-label, Phase II Study to Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT06812260: https://clinicaltrials.gov/study/NCT06812260

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06812260.json